A J van der Lely

Summary

Affiliation: Erasmus Medisch Centrum
Country: The Netherlands

Publications

  1. ncbi Hormone use and abuse: what is the difference between hormones as fountain of youth and doping in sports?
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 26:932-6. 2003
  2. ncbi Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
    A J van der Lely
    Erasmus Medical Centre Rotterdam, 40 Dr Molewaterplein, 3015 GD, Rotterdam, Netherlands
    Lancet 358:1754-9. 2001
  3. ncbi Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
    A J van der Lely
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 86:478-81. 2001
  4. ncbi Use of human GH in elderly patients with accidental hip fracture
    A J van der Lely
    Erasmus University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 143:585-92. 2000
  5. ncbi Octreoscan radioreceptor imaging
    Aart J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Endocrine 20:307-11. 2003
  6. ncbi A risk-benefit assessment of octreotide in the treatment of acromegaly
    A J van der Lely
    Department of Internal Medicine, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
    Drug Saf 17:317-24. 1997
  7. ncbi Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion
    A F Muller
    Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 55:461-7. 2001
  8. ncbi Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease
    R van der Pas
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Room Ee 569, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Pituitary 16:536-44. 2013
  9. ncbi Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance
    A F Muller
    Department of Internal Medicine, Erasmus Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
    J Clin Endocrinol Metab 86:590-3. 2001
  10. ncbi Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency
    A F Muller
    Department of Internal Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 86:5165-71. 2001

Collaborators

Detail Information

Publications64

  1. ncbi Hormone use and abuse: what is the difference between hormones as fountain of youth and doping in sports?
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 26:932-6. 2003
    ..The abuse of GH by sportsmen is based on the belief that it has potent anabolic effects, while it is difficult to detect the abuse. Again, this supposed efficacy cannot be supported by any scientific data...
  2. ncbi Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
    A J van der Lely
    Erasmus Medical Centre Rotterdam, 40 Dr Molewaterplein, 3015 GD, Rotterdam, Netherlands
    Lancet 358:1754-9. 2001
    ..We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days...
  3. ncbi Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
    A J van der Lely
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 86:478-81. 2001
    ..The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects...
  4. ncbi Use of human GH in elderly patients with accidental hip fracture
    A J van der Lely
    Erasmus University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 143:585-92. 2000
    ..To investigate whether early intervention with recombinant human growth hormone (hGH) after hip fracture improves functional recovery and long-term outcome...
  5. ncbi Octreoscan radioreceptor imaging
    Aart J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Endocrine 20:307-11. 2003
    ..The value of somatostatin receptor imaging in patients with other tumors, like breast cancer, or in patients with granulomatous diseases, has to be established...
  6. ncbi A risk-benefit assessment of octreotide in the treatment of acromegaly
    A J van der Lely
    Department of Internal Medicine, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
    Drug Saf 17:317-24. 1997
    ..Desensitisation to the beneficial effects of octreotide therapy is highly unusual. A long-acting formulation of octreotide is being studied, and should be available by the end of 1997...
  7. ncbi Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion
    A F Muller
    Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 55:461-7. 2001
    ..Pegvisomant is a mutated GH molecule which prevents functional dimerization and subsequent activation of the growth hormone receptor. Pegvisomant and fasting both lead to GH resistance...
  8. ncbi Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease
    R van der Pas
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Room Ee 569, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Pituitary 16:536-44. 2013
    ..Despite the occurrence of side-effects, QoL does not deteriorate after short-term biochemical remission induced by medical therapy, but might improve after sustained control of hypercortisolism...
  9. ncbi Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance
    A F Muller
    Department of Internal Medicine, Erasmus Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
    J Clin Endocrinol Metab 86:590-3. 2001
    ..As a mechanism of these GHRP-6-mediated metabolic changes in the nonfasting state, direct nonpituitary-mediated GHRP-6 effects on the gastroentero-hepatic axis seem probable...
  10. ncbi Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency
    A F Muller
    Department of Internal Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 86:5165-71. 2001
    ..These data suggest that the secondary metabolic changes, e.g. abdominal obesity or inflammatory factors, that develop as a result of long-standing GHD are of primary importance in the pathogenesis of atherosclerosis in patients with GHD...
  11. doi Biochemical predictors of outcome of pituitary surgery for Cushing's disease
    R A Alwani
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Neuroendocrinology 91:169-78. 2010
    ..The aims of this retrospective study were twofold: (i) investigate early and late results of TS for CD, and (ii) evaluate various postoperative tests in order to predict the outcome of TS...
  12. doi Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
    S J C M M Neggers
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:3853-9. 2008
    ....
  13. doi Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
    S J C M M Neggers
    Department of Medicine, Erasmus University, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 160:529-33. 2009
    ..We previously reported on the efficacy, safety, and quality of life (QoL) of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA...
  14. ncbi Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
    J Feenstra
    Department of Internal Medicine, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, Netherlands
    Lancet 365:1644-6. 2005
    ..This combined treatment is effective, might increase compliance, and could greatly reduce the costs of medical treatment for acromegaly in some patients...
  15. doi Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors
    R A Feelders
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Drugs Today (Barc) 49:89-103. 2013
    ....
  16. ncbi Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects
    L J Hofland
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 28:36-42. 2005
    ..However, every advantage has its disadvantage. Targeting multiple SSTR potentially induces more adverse effects as well. Especially, glucose homeostasis might induce new problems in the long-term use of universal ligands...
  17. doi Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests
    R A Alwani
    Division of Endocrinology, Room H555, Department of Internal Medicine, Erasmus Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Eur J Endocrinol 170:477-86. 2014
    ..To evaluate the diagnostic performance of four different tests in order to differentiate between Cushing's disease (CD) and pseudo-Cushing's syndrome (PCS)...
  18. ncbi Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans
    F Broglio
    Division of Endocrinology, Department of Internal Medicine, Erasmus University of Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:3062-5. 2004
    ..As GHS-R1a is not bound by unacylated ghrelin, these findings suggest that GHS receptor subtypes mediate the metabolic actions of both acylated and unacylated ghrelin...
  19. doi Ghrelin and glucose homeostasis
    P J D Delhanty
    Department of Internal Medicine, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Peptides 32:2309-18. 2011
    ..A promising recently developed approach appears to be through the blockade of GOAT activity, although the longer term effects of this treatment remain to be investigated...
  20. ncbi Neuroendocrine tumors and somatostatin: imaging techniques
    W W de Herder
    Section of Endocrinology, Department of Internal Medicine, Erasmus Rotterdam, The Netherlands
    J Endocrinol Invest 28:132-6. 2005
    ..A large variety of lesions in and around the pituitary region express somatostatin receptors and, therefore, can be visualized by 111In-pentetreotide scintigraphy...
  21. ncbi Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant
    J Feenstra
    Department of Internal Medicine, Edocrinology Unit, Erasums Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Eur J Endocrinol 154:805-6. 2006
    ..Clinicians should be aware of this potential severe adverse drug reaction and therefore frequent control of hepatic enzymes is mandatory during treatment with pegvisomant...
  22. ncbi Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
    R A Feelders
    Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 90:6480-9. 2005
    ..It is not exactly known when patients with acromegaly should be evaluated for cure after transsphenoidal adenomectomy (TA)...
  23. pmc Somatostatin analogue treatment of neuroendocrine tumours
    W W de Herder
    Department of Internal Medicine III, University Hospital, Rotterdam, Netherlands
    Postgrad Med J 72:403-8. 1996
    ..Long-term therapy with somatostatin analogues of catecholamine-secreting (malignant) paragangliomas and phaeochromocytomas has not shown clinical benefits...
  24. ncbi Somatostatin, cortistatin, ghrelin and glucose metabolism
    C Gauna
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Endocrinol Invest 28:127-31. 2005
    ....
  25. ncbi [Growth hormone receptor antagonists: potential indications]
    A F Muller
    Erasmus Universitair Medisch Centrum, afd Inwendige Geneeskunde, Dr Molewaterplein 40, 3015 GD Rotterdam
    Ned Tijdschr Geneeskd 145:69-73. 2001
    ..Animal studies in which human colon and breast cancer models were used showed that pegvisomant can powerfully decrease tumour growth. Studies in cancer patients have not yet started...
  26. doi Unsaturated fatty acids prevent desensitization of the human growth hormone secretagogue receptor by blocking its internalization
    Patric J D Delhanty
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 299:E497-505. 2010
    ....
  27. doi Combination treatment with somatostatin analogues and pegvisomant in acromegaly
    S J C M M Neggers
    Department of Medicine, Section Endocrinology, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Growth Horm IGF Res 21:129-33. 2011
    ..Transient elevations in the levels of transaminases are the main adverse effects of combination treatment, which occur in about 11-15% of patients...
  28. doi Rapid decrease in adrenal responsiveness to ACTH stimulation after successful pituitary surgery in patients with Cushing's disease
    R A Alwani
    Department of Internal Medicine, Endocrine Section, Erasmus Medical Centre, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 75:602-7. 2011
    ..The aim of this study was to investigate the effects of transsphenoidal surgery (TS) on the adrenal sensitivity to ACTH (adrenocorticotropin) stimulation in patients with Cushing's disease (CD)...
  29. ncbi Pharmacotherapy or surgery as primary treatment for acromegaly?
    D Ferone
    Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands
    Drugs Aging 17:81-92. 2000
    ..Moreover, a multidisciplinary team of well trained specialists is needed in order to guarantee the most optimal quality of life and life expectancy for patients with acromegaly...
  30. ncbi Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway
    P J D Delhanty
    Department of Internal Medicine, Rm Ee542, Erasmus Medical Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 293:E302-9. 2007
    ....
  31. doi Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer
    W van Dorp
    Department of Paediatric Oncology Haematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands
    Eur J Endocrinol 168:905-12. 2013
    ..In the general population, obesity has a negative influence on female fertility. We aimed to evaluate whether obesity and serum insulin are associated with decreased ovarian reserve markers in CCS...
  32. pmc Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
    Sebastian J C M M Neggers
    Department of Medicine, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pituitary 14:253-8. 2011
    ..However, there seems to be a wide variation in the reduction of PEG-V dose, which can be obtained after conversion to combined treatment...
  33. ncbi Unacylated ghrelin is not a functional antagonist but a full agonist of the type 1a growth hormone secretagogue receptor (GHS-R)
    Carlotta Gauna
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Mol Cell Endocrinol 274:30-4. 2007
    ..Where local concentrations of UAG may reach the high nanomolar to micromolar range, assignment of GHS-R independent effects should be made with caution...
  34. ncbi Growth hormone receptor antagonists
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 83:264-8. 2006
    ..Also, pegvisomant monotherapy is administered once daily and is very costly. Combined treatment of a somatostatin analog with pegvisomant appears to be an effective and rational approach...
  35. ncbi There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Endocrinol Invest 27:659-64. 2004
    ..This suggests that GH-independent effects of ghrelin play no important role in the acute regulation of cardiac function in man...
  36. doi Final height and IGF1 in adult survivors of Wilms tumour
    K Blijdorp
    Department of Paediatric Oncology Haematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    Eur J Endocrinol 169:445-51. 2013
    ..The aim was to evaluate final height and IGF1 levels in nephrectomized Wilms tumour survivors when compared with healthy Dutch references and survivors of other cancer types...
  37. ncbi The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy
    R van der Pas
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Room Ee 569, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:1303-10. 2012
    ..Cushing's disease (CD) is accompanied by an increased risk of venous thromboembolism. Surgery is the primary treatment of CD...
  38. doi What is active acromegaly and which parameters do we have?
    S J C M M Neggers
    Department of Medicine, Section Endocrinology, Erasmus University Medical Center Rotterdam, CA Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 76:609-14. 2012
    ..Both GH and IGF1 have been associated with prognosis, in particular mortality. In this review, we discuss the available parameters to assess disease activity in acromegaly...
  39. ncbi The endocrinology of aging
    S W Lamberts
    Department of Medicine, Erasmus University, Rotterdam, Netherlands
    Science 278:419-24. 1997
    ....
  40. ncbi Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours
    W W de Herder
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 10:451-8. 2003
    ..Currently, [(111)In-DTPA(0)]octreotide, [(90)Y-DOTA(0),Tyr(3)]octreotide, [(177)Lu-DOTA(0)Tyr(3)]octreotate, [(111)In-DOTA(0)]lanreotide and [(90)Y-DOTA(0)]lanreotide can be used for this purpose...
  41. doi Pegvisomant and improvement of quality of life in acromegalic patients
    S J Neggers
    Department of Medicine, Erasmus University, Rotterdam, The Netherlands
    Horm Res Paediatr 76:102-5. 2011
    ..The remaining 'peripheral' or non- hepatic acromegaly has a significant negative impact on the quality of life of these patients...
  42. ncbi Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 26:588-94. 2003
    ..Therefore, when evaluating the IGF-I bioactivity in health and disease, we recommend measuring also circulating free IGF-I...
  43. ncbi Is there a role of ghrelin in preventing catabolism?
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 27:400-3. 2004
    ..In conclusion, the anabolic effects of ghrelin in man have still to be demonstrated...
  44. ncbi [Still no indications that the treatment of growth hormone deficient adults with growth hormones is unsafe]
    J A M J L Janssen
    Erasmus Medisch Centrum, afd Inwendige Geneeskunde, sectie Endocrinologie, Dr Molewaterplein 40, 3015 GD Rotterdam
    Ned Tijdschr Geneeskd 148:1486-9. 2004
    ..Whether growth-hormone therapy in adult patients with GHD will prove safe in the long term remains to be established...
  45. ncbi The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state
    F Broglio
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Erasmus University, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 60:592-9. 2004
    ..The aim of this study was to define the endocrine actions of ghrelin in patients with anorexia nervosa...
  46. doi Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma
    R A Alwani
    Department of Internal Medicine, Endocrine Section, Rotterdam, The Netherlands
    Pituitary 12:280-3. 2009
    ..Although a rare cause of ectopic ACTH production, neuroendocrine prostate carcinoma should be considered in male patients with Cushing's syndrome, in particular in those with an occult source of ACTH overproduction...
  47. ncbi Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a
    P J D Delhanty
    Department of Internal Medicine, Erasmus Medical Centre, Dr Molewaterplein 50, 3015 GD Rotterdam, The Netherlands
    J Endocrinol 188:37-47. 2006
    ..Overall, our data suggest new roles for ghrelin and UAG in modulating human osteoblast proliferation via a novel signal transduction pathway...
  48. ncbi Growth hormone and glucose metabolism: the model of the GH-receptor antagonists
    A J van der Lely
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Erasmus Medical Center, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Ann Endocrinol (Paris) 65:81-3. 2004
    ..However, there are simply no data available that might support a role for pegvisomant treatment in disorders in which glucose metabolism is disturbed and in which reducing GH action would be theoretically beneficial...
  49. ncbi New somatostatin analogs: will they fulfil old promises?
    S W J Lamberts
    Department of Medicine, Erasmus Medical Centre, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 146:701-5. 2002
  50. pmc Justified and unjustified use of growth hormone
    A J van der Lely
    Department of Internal Medicine, Erasmus MC, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Postgrad Med J 80:577-80. 2004
    ..Moreover, there are no available study data to indicate that the use of GH for non-GH deficient subjects should be advocated, especially as animal data suggest that lower GH levels are positively correlated with longevity...
  51. ncbi Pituitary function during severe and life-threatening illnesses
    C Gauna
    Department of Internal Medicine, Head of Endocrinology, Erasmus MC, CA Rotterdam, The Netherlands
    Pituitary 8:213-7. 2005
    ....
  52. doi Acute effects of acylated and unacylated ghrelin on total and high molecular weight adiponectin inmorbidly obese subjects
    R M Kiewiet
    Division of Endocrinology, Department of Internal Medicine, Erasmus University Medical Centre, CA Rotterdam, The Netherlands
    J Endocrinol Invest 34:434-8. 2011
    ....
  53. ncbi Cerebrospinal fluid leakage during transsphenoidal surgery: postoperative external lumbar drainage reduces the risk for meningitis
    M O van Aken
    Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Pituitary 7:89-93. 2004
    ..Possibly, diversion of CSF prevents the formation of a CSF fistula and thereby the risk of infection. The role of prophylactic antibiotic treatment in patients with CSF rhinorrhea after TSS remains to be established...
  54. ncbi Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans
    F Broglio
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    J Endocrinol Invest 26:192-6. 2003
    ..In conclusion, this study shows that in humans nonacylated ghrelin does not possess the pituitaric and pancreatic endocrine activities of human ghrelin octanoylated in Serine 3...
  55. ncbi Ghrelin: a link between eating disorders, obesity and reproduction
    C Gottero
    Department of Internal Medicine, University of Turin, 10126 Turin, Italy
    Nutr Neurosci 7:255-70. 2004
    ....
  56. ncbi d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans
    A Benso
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    Neuropeptides 41:45-9. 2007
    ..25microg/kg iv acylated ghrelin. In conclusion, D-Lys-GHRP-6 does not affect the neuroendocrine response to both ghrelin and hexarelin. These findings question D-Lys-GHRP-6 as an effective GHS-R1a antagonist for human studies...
  57. ncbi Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans
    F Broglio
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, 10126 Turin, Italy
    J Clin Endocrinol Metab 86:5083-6. 2001
    ....
  58. ncbi Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity
    C Gauna
    Department of Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:5035-42. 2004
    ....
  59. ncbi Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans
    F Broglio
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, 10126 Torino, Italy
    J Clin Endocrinol Metab 88:4268-72. 2003
    ..These findings support the hypothesis that ghrelin exerts modulatory action of insulin secretion and glucose metabolism in humans...
  60. ncbi Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans
    A Benso
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy
    J Endocrinol Invest 26:599-603. 2003
    ..Like SS-14, CST-14 also inhibits insulin secretion but both do not modify the stimulatory effects of HEX on lactotroph and corticotroph secretion. Thus, CST-14 exerts full SS-14 activity in humans...
  61. ncbi Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity
    F Tassone
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, 10126 Turin, Italy
    J Clin Endocrinol Metab 88:5478-83. 2003
    ..On the other hand, in obesity ghrelin shows preserved influence on PRL, ACTH, and insulin secretion as well as in glucose levels...
  62. ncbi Cortistatin-8, a synthetic cortistatin-derived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans
    F Prodam
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy
    Neuropeptides 42:89-93. 2008
    ..However, these data strongly suggest that CST-8 is not a promising candidate as GHS-R1a antagonist for human studies to explore the functional interaction between ghrelin and cortistatin systems...
  63. ncbi Cortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans
    C Gottero
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, C so Dogliotti 14, 10126 Turin, Italy
    Growth Horm IGF Res 14:382-7. 2004
    ..In conclusion, this study demonstrates that human CST-17 and rat CST-14 exert the same endocrine activities of SS in humans. The endocrine actions of human and rat CST therefore are likely to reflect activation of classical SS receptors...
  64. doi By studying ageing, endocrinology stays young
    A J van der Lely
    Nat Clin Pract Endocrinol Metab 4:473. 2008